Mode
Text Size
Log in / Sign up
Phase 4 N=140 Randomized Quadruple-blind Other

Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy

Shoulder Arthroscopy · Pain

Enrolled (actual)
140
Serious AEs
0.0%
Results posted
May 2022
Primary outcome: Primary: Duration of Analgesia From a Supraclavicular Block Performed for Shoulder Arthroscopy — 17.4; 22.7; 20.2; 19.8 Hours

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
IV Saline (Drug); IV Dexamethasone 4mg (Drug); IV Dexamethasone 6mg (Drug); IV Dexamethasone 8mg (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Hospital for Special Surgery, New York
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Duration of Analgesia From a Supraclavicular Block Performed for Shoulder Arthroscopy
17.4; 22.7; 20.2; 19.8
SECONDARY
Duration of Motor Block From the Supraclavicular Block
10.5; 19.7; 18.3; 14.7
SECONDARY
Blood Glucose Levels
102; 108; 104; 105; 119; 122
SECONDARY
Occurrence of Postoperative Neuropraxia
0; 1; 0; 0
SECONDARY
Occurrence of Postoperative Wound Infection
0; 0; 0; 0
SECONDARY
Average Daily Pain Scores at Rest and With Movement
2.6; 3; 2.4; 2.5; 0.4; 0.2
SECONDARY
Worst Daily Pain Scores at Rest and With Movement
3.4; 3.3; 3.4; 3.6; 0.6; 0.2
SECONDARY
Patient Satisfaction With Postoperative Analgesia
9.1; 8.9; 9.2; 8.7
SECONDARY
Cumulative Daily Opioid Usage
31; 30.5; 30.7; 31.3; 22.3; 27.4

Summary

Previous studies have confirmed that IV dexamethasone prolongs brachial plexus blocks. However, these studies only used fixed doses of IV dexamethasone at relatively high doses, which could potentially lead to increased glucose levels, delayed wound healing, and unintended side effects. There remains a paucity of research on the effective dose range of IV dexamethasone for the prolongation of supraclavicular blocks. The optimal dosage of IV dexamethasone for prolongation of analgesia vs. motor block prolongation from supraclavicular blocks in shoulder surgery has yet to be delineated.

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing shoulder arthroscopy under regional anesthesia

Exclusion Criteria

  • General anesthesia
  • Contraindication to regional anesthesia
  • Pre-existing neuropathy in the surgical limb
  • Diabetes Mellitus
  • History of postoperative nausea and vomiting &/ or motion sickness
  • Procedures involving biceps tenotomy
  • Peri-articular cocktail injections given intraoperatively to augment pain relief
  • Chronic pain (daily opioid and/or gabapentinoid use for 6 weeks)
  • Open surgical procedures
  • Corticosteroid injection within 1 month
  • Patients on systemic oral or IV steroid therapy within 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02688530). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search